# Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

> **NCT00005072** · PHASE1,PHASE2 · TERMINATED · sponsor: **Vical** · enrollment: 25 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Leuvectin

## Key facts

- **NCT ID:** NCT00005072
- **Lead sponsor:** Vical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-11
- **Primary completion:** 2003-04
- **Final completion:** 2003-04
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Development in prostate cancer indication halted
- **Last updated:** 2014-07-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005072, "Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00005072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*